Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Other Operating Expenses: 2019-2020

Historic Other Operating Expenses for Keros Therapeutics (KROS) over the last 1 years, with Mar 2020 value amounting to -$1.5 million.

  • Keros Therapeutics' Other Operating Expenses fell 146.69% to -$1.5 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$3.5 million, marking a year-over-year change of. This contributed to the annual value of -$1.5 million for FY2020, which is 41.89% up from last year.
  • Per Keros Therapeutics' latest filing, its Other Operating Expenses stood at -$1.5 million for Q1 2020, which was down 1,810.26% from -$78,000 recorded in Q4 2019.
  • Over the past 5 years, Keros Therapeutics' Other Operating Expenses peaked at -$78,000 during Q4 2019, and registered a low of -$1.5 million during Q1 2020.
  • In the last 2 years, Keros Therapeutics' Other Operating Expenses had a median value of -$647,000 in 2019 and averaged -$810,800.
  • Data for Keros Therapeutics' Other Operating Expenses shows a maximum YoY slumped of 146.69% (in 2020) over the last 5 years.
  • Quarterly analysis of 2 years shows Keros Therapeutics' Other Operating Expenses stood at -$78,000 in 2019, then crashed by 146.69% to -$1.5 million in 2020.
  • Its Other Operating Expenses was -$1.5 million in Q1 2020, compared to -$78,000 in Q4 2019 and -$1.2 million in Q3 2019.